Aspirin Use Cuts CRC Risk in Those Initiating Use Before Age 70

THURSDAY, Jan. 21, 2021 -- Regular use of aspirin is associated with a reduced risk for colorectal cancer (CRC) among those with initiation of aspirin before age 70 years, according to a study published online Jan. 21 in JAMA Oncology.

Chuan Guo-Guo, M.Med., from Massachusetts General Hospital in Boston, and colleagues examined the correlation between aspirin use and risk for incident CRC among older adults in a pooled analysis conducted using the Nurses' Health Study and the Health Professionals Follow-up Study. Data were included for 94,540 participants aged 70 years or older.

The researchers identified 1,431 incident cases of CRC during 996,463 person-years of follow-up. Compared with nonregular use, regular use of aspirin was associated with a significantly reduced risk for CRC at or after age 70 years after adjustment for other risk factors (hazard ratio, 0.80; 95 percent confidence interval, 0.72 to 0.90). The inverse association was only seen among aspirin users who initiated use before age 70 years (hazard ratio, 0.80; 95 percent confidence interval, 0.67 to 0.95), while risk was not reduced with initiation of aspirin at or after age 70 years (hazard ratio, 0.92; 95 percent confidence interval, 0.76 to 1.11).

"These findings suggest that initiation of aspirin use at an older age for the sole purpose of primary prevention of CRC should be discouraged," the authors write. "However, our findings appear to support recommendations to continue aspirin use if initiated at a younger age."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Posted: January 2021

Read this next

Colorectal Cancer Risk From Obesity Varies by Sex

MONDAY, Jan. 11, 2021 -- Higher body mass index (BMI) is associated with a significantly increased risk for colorectal cancer (CRC) among men, whereas higher waist-to-hip ratio...

Triple Treatment Combo Beneficial in BRAF-Mutant CRC

MONDAY, Dec. 28, 2020 -- Irinotecan and cetuximab combined with vemurafenib improve progression-free survival in BRAFV600E-mutated colorectal cancer (CRC), according to a study...

Early-Onset CRC Incidence Examined by Histologic Subtype

MONDAY, Dec. 21, 2020 -- Among individuals with early-onset colorectal cancer (EOCRC), adenocarcinoma rates are increasing in specific subgroups, but carcinoid tumors are...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.